AAIFNC 2023 Annual Symposium
The 2023 Annual Symposium program will provide continuing medical education on Food Allergy and Diagnosis, Anaphylaxis, treatment options in AERD, Asthma (childhood asthma and precision medicine), Mast Cell Disorders, and Immunodeficiency. It's goal is to promote knowledge and understanding of allergies, asthma, and clinical immunology through advocacy and education.
The Allergy, Asthma & Immunology Foundation of Northern California (AAIFNC) is a nonprofit Foundation whose members are physicians and other medical professionals specializing in allergy and immunology. Our primary purpose is to encourage the association of medical professionals specializing in allergy, asthma, and immunology to study current issues and developments relevant to the specialty and the continuing education of those medical professionals.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma and Immunology Foundation of Northern California (AAIFNC). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239 for 7.0 contact hours.
Target Audience
Allergists
Allied Health Professionals
Learning Objectives
At the conclusion of this activity, learners should be able to:
1. Describe the cardinal manifestations of immune deficiencies and how to distinguish these immune defects.
2. Evaluate strategies for treatment of patients with AERD based on guidelines and recent clinical data.
3. Understand and describe the process involved in the diagnosis of food allergy.
4. Review clinical data on treatment options for mast cell activation disease.
5. Using updated guidelines, evaluate and select evolving therapeutic strategies for treatment of asthma.
Annual Symposium, “Bridges to Understanding”
Saturday, April 29, 2023
6:15AM-7:55AM Registration, Exhibits & Coffee Break
7:55AM-8:00AM PROGRAM INTRODUCTION and WELCOME
Steve Machtinger, MD and Joshua Jacobs, MD Session Moderator
8:00AM-8:50AM Understanding and Applying the Best Approaches to Food Allergy Diagnosis
Scott Sicherer, MD
8:50AM-9:40AM Anaphylaxis: Using the Updated 2023 Guidelines for Difficult and Controversial Decisions
Dana Wallace, MD
9:40AM-10:30AM Comparing Treatment Options in AERD
Drew White, MD
10:50AM-11:20AM Exhibits, Posters, Coffee Break
11:20AM-12:10PM Precision Medicine for Asthma in 2023: Where Are We Now?
Monica Kraft, MD
12:10PM-1:00PM Childhood Asthma and Obesity: Is Insulin Resistance the Link?
Fernando D. Martinez, MD
1:00PM-2:05PM Lunch Break & Exhibits
2:10PM-3:00PM Mast Cell Disorders: Controversies and New Treatments
Cem Akin, MD, PhD
3:00PM-3:50PM Immune Deficiency Secondary to B-cell Targeted Therapies
Elie Haddad, MD, PhD
3:50PM-4:40PM CVID: New and Upcoming Causes of Immune Deficiency
Troy Torgerson, MD, PHD
4:40PM-5:00PM Q&A: Immunodeficiency
Ellie Haddad, MD, PhD & Troy Torgerson, MD, PhD
5:00PM-5:05PM Acknowledgements & Wrap-Up
Steve Machtinger, MD – AAIFNC President
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All relevant financial relationships with ineligible companies have been mitigated.
The individuals listed below disclose the following financial relationships:
Cem Akin, MD, PhD: Speaker
Researcher: Blueprint Medicines, Cogent
Consultant: Blueprint Medicines, Cogent, Novartis
Elie Haddad, MD, PhD: Speaker
Advisor: Octopharma, Jasper Therapeutics, CSL Behring, Takeda
Monica Kraft, MD: Speaker
Contractor: AstraZeneca
Speaker: Chiesi
Consultant: Chiesi, Synairgen, Kinaset
Ownership Interest: RaeSedi, Inc.
Executive Role: RaeSedi, Inc.
Independent contractor: Synairgen, Sanofi
Troy R. Torgerson, MD, PhD: Speaker
Advisor: Takeda, Pharming Healthcare
Consultant: Takeda, X4 Pharmaceuticals, Horizon Therapeutics
Researcher: Eli Lilly
Dana Wallace, MD: Speaker
Advisor: Sanofi
Consultant: Bryn
Drew White, MD: Speaker
Advisor: Regeneron/Sanofi
Speaker: Regeneron/Sanofi
Researcher: Regeneron/Sanofi
A. Carmen Choy, MD: Planner
Stock: Regeneron
Josh Jacobs, MD: Planner
Researcher: Teva, AstraZeneca, Regeneron, Genentech, Novartis, Allakos, Ionis Pharmaceuticals, Pharvaris, Aimmune, ADMA, CSL Behring, Takeda, BioCryst
Speaker: BioCryst, Blueprint Medicines, AstraZeneca, Amgen, Regeneron, Sanofi, GSK, Takeda, Teva, Grifols
Ownership Interest: Regeneron
Gregory Bensch, MD: Planner
Advisor: Sanofi/Regeneron, Aimmune, AstraZeneca
Consultant: Sanofi/Regeneron,
Speaker: Sanofi/Regeneron, Aimmune, Teva, AstraZeneca, Blueprint Medicines, Incyte
The following have no relevant financial relationships with ineligible companies to disclose:
Fernando D. Martinez, MD: Speaker
Scott Sicherer, MD: Speaker
Steve Machtinger, MD: Planner
Kristina H. Philpott, MD: Planner
Javaid M. Khan, DO: Planner
Sean McGhee, MD, PhD: Planner
Iris Otani, MD: Planner
Sarah Pederson, RN: Planner
Michael Reid, MD: Planner
Karol Anderson: Planner
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma and Immunology Foundation of Northern California ((AAIFNC). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of XXX AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 0.0 contact hours.
Available Credit
- 7.00 AMA PRA Category 1 Credit™
- 7.00 Attendance
- 7.00 CBRN